×
About 27,734 results

ALLMedicine™ Severe Acute Respiratory Syndrome Center

Research & Reviews  13,289 results

From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059477
Mediators of Inflammation; Ahmadi Badi S, Tarashi S et. al.

May 6th, 2021 - Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of a new viral respiratory infection. It has been demonstrated that the microbiota has a crucial role in establishing immune responses against respiratory...

Zebrafish as a translational model: an experimental alternative to study the mechanisms...
https://doi.org/10.1523/ENEURO.0027-21.2021
ENeuro Costa KCM, Brigante TAV et. al.

May 6th, 2021 - The Coronavirus Disease - 2019 (COVID-19) presents a variability of clinical symptoms, ranging from asymptomatic to severe respiratory and systemic conditions. In a cohort of patients, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)...

Role of the Immune Microenvironment in SARS-CoV-2 Infection.
https://doi.org/10.1177/09636897211010632
Cell Transplantation; Ye CH, Hsu WL et. al.

May 5th, 2021 - Severe acute respiratory syndrome coronavirus (SARS-CoV-2) first emerged in December 2019 in Wuhan, China, and has since spread rapidly worldwide. As researchers seek to learn more about COVID-19, the disease it causes, this novel virus continues ...

Salivary testing of COVID-19: evaluation of serological testing following positive sali...
https://doi.org/10.1186/s12879-021-06108-5 10.1056/NEJMc2016359 10.3201/eid2611.203283 10.1128/JCM.01946-20 10.1016/S2666-5247(20)30120-8 10.1016/S0140-6736(20)32137-1 10.1016/j.immuni.2020.10.004 10.1056/NEJMc2025179
BMC Infectious Diseases; Caulley L, Shaw J et. al.

May 5th, 2021 - Salivary detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proposed as an alternative to nasopharyngeal or oropharyngeal swab testing. Our group previously published a study demonstrating that both testing methods ...

see more →

Guidelines  249 results

Management of maternal COVID-19: considerations for anesthesiologists.
https://doi.org/10.1097/ACO.0000000000001001
Current Opinion in Anaesthesiology; Bernstein K, Landau R

Apr 19th, 2021 - To describe updates to pragmatic recommendations that were published during the first coronavirus disease 2019 (COVID-19) surge, including the current thinking about whether pregnancy worsens the severity of COVID-19. Although a majority of pregna...

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
https://www.nejm.org/doi/full/10.1056/NEJMc2106075?query=featured_home
New England Journal of Medicine; Sadoff J, .

Apr 15th, 2021 - A case report by Muir et al.1 describes thrombosis, including cerebral venous sinus thrombosis (CVST), associated with severe thrombocytopenia and disseminated intravascular coagulation in a recipient of the Ad26.COV2.S vaccine (Johnson & Johnson/...

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
https://www.nejm.org/doi/full/10.1056/NEJMc2103825?query=featured_coronavirus
New England Journal of Medicine; Anichini G, .

Apr 12th, 2021 - Whether or not persons who have already been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be vaccinated is unclear. Only a few studies have shown that vaccinees who were previously infected with SARS-CoV-2 had ...

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
https://www.nejm.org/doi/full/10.1056/NEJMc2101667
New England Journal of Medicine; Krammer F, Srivastava K et. al.

Apr 7th, 2021 - The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without p...

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.

Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  13,653 results

From the Role of Microbiota in Gut-Lung Axis to SARS-CoV-2 Pathogenesis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059477
Mediators of Inflammation; Ahmadi Badi S, Tarashi S et. al.

May 6th, 2021 - Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of a new viral respiratory infection. It has been demonstrated that the microbiota has a crucial role in establishing immune responses against respiratory...

Zebrafish as a translational model: an experimental alternative to study the mechanisms...
https://doi.org/10.1523/ENEURO.0027-21.2021
ENeuro Costa KCM, Brigante TAV et. al.

May 6th, 2021 - The Coronavirus Disease - 2019 (COVID-19) presents a variability of clinical symptoms, ranging from asymptomatic to severe respiratory and systemic conditions. In a cohort of patients, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)...

Role of the Immune Microenvironment in SARS-CoV-2 Infection.
https://doi.org/10.1177/09636897211010632
Cell Transplantation; Ye CH, Hsu WL et. al.

May 5th, 2021 - Severe acute respiratory syndrome coronavirus (SARS-CoV-2) first emerged in December 2019 in Wuhan, China, and has since spread rapidly worldwide. As researchers seek to learn more about COVID-19, the disease it causes, this novel virus continues ...

Salivary testing of COVID-19: evaluation of serological testing following positive sali...
https://doi.org/10.1186/s12879-021-06108-5 10.1056/NEJMc2016359 10.3201/eid2611.203283 10.1128/JCM.01946-20 10.1016/S2666-5247(20)30120-8 10.1016/S0140-6736(20)32137-1 10.1016/j.immuni.2020.10.004 10.1056/NEJMc2025179
BMC Infectious Diseases; Caulley L, Shaw J et. al.

May 5th, 2021 - Salivary detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proposed as an alternative to nasopharyngeal or oropharyngeal swab testing. Our group previously published a study demonstrating that both testing methods ...

see more →

News  535 results

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
https://www.nejm.org/doi/full/10.1056/NEJMc2106075?query=featured_home
New England Journal of Medicine; Sadoff J, .

Apr 15th, 2021 - A case report by Muir et al.1 describes thrombosis, including cerebral venous sinus thrombosis (CVST), associated with severe thrombocytopenia and disseminated intravascular coagulation in a recipient of the Ad26.COV2.S vaccine (Johnson & Johnson/...

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
https://www.nejm.org/doi/full/10.1056/NEJMc2103825?query=featured_coronavirus
New England Journal of Medicine; Anichini G, .

Apr 12th, 2021 - Whether or not persons who have already been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be vaccinated is unclear. Only a few studies have shown that vaccinees who were previously infected with SARS-CoV-2 had ...

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
https://www.nejm.org/doi/full/10.1056/NEJMc2101667
New England Journal of Medicine; Krammer F, Srivastava K et. al.

Apr 7th, 2021 - The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without p...

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.

Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...

Post-acute COVID-19 syndrome
https://www.nature.com/articles/s41591-021-01283-z
Nature Medicine; Nalbandian, A. et. al.

Mar 21st, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patie...

see more →

Patient Education  7 results see all →